Tag: US National Institutes of Health
US NIH stops ACTIV-2 phase 3 trial of Covid-19 drug candidate SAB-185
SAB Biotherapeutics said that the US National Institutes of Health (NIH) is discontinuing the phase 3 ACTIV-2 trial of the company’s SAB-185 for the treatment ... Read More
ReveraGen, Santhera get FDA grant for BMD trial of vamorolone
ReveraGen Biopharma and Santhera Pharmaceuticals have secured a $1.2 million grant for funding their clinical trial of vamorolone in Becker muscular dystrophy (BMD) from the ... Read More